Supplemental Table S6 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
posted on 2023-04-04, 01:46authored byRyon P. Graf, Virginia Fisher, James Creeden, Alexa B. Schrock, Jeffrey S. Ross, Halla Nimeiri, Geoffrey R. Oxnard, Samuel J. Klempner
Summary of TMB ranges per cohort and PD-L1. The median and interquartile range of TMB is shown per group within the cohorts, grouped by PD-L1 status.
Funding
AGA Research Foundation (American Gastroenterological Association (AGA) Research Foundation)
History
ARTICLE ABSTRACT
Using real-world data, we sought to evaluate robustness of these clinical associations using the same assay platform and biomarker cut-off point used in both clinical trials and pan-tumor CDx approvals for later treatment lines. TMB ≥ 10 robustly identified patients with mEG with more favorable outcomes on ICPI monotherapy versus chemotherapy and suggests this subset of patients could be targeted for further trial development.